First Fiduciary Investment Counsel Inc. lessened its stake in shares of Novartis AG (NYSE:NVS – Free Report) by 1.2% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 144,004 shares of the company’s stock after selling 1,727 shares during the quarter. Novartis comprises 3.2% of First Fiduciary Investment Counsel Inc.’s portfolio, making the stock its 9th largest holding. First Fiduciary Investment Counsel Inc.’s holdings in Novartis were worth $14,540,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds have also added to or reduced their stakes in the company. Operose Advisors LLC purchased a new position in Novartis during the 3rd quarter valued at about $28,000. Planned Solutions Inc. purchased a new position in Novartis during the 4th quarter valued at about $31,000. AdvisorNet Financial Inc grew its holdings in Novartis by 480.0% during the 4th quarter. AdvisorNet Financial Inc now owns 348 shares of the company’s stock valued at $35,000 after buying an additional 288 shares in the last quarter. Annis Gardner Whiting Capital Advisors LLC purchased a new position in Novartis during the 3rd quarter valued at about $39,000. Finally, Adirondack Trust Co. grew its holdings in shares of Novartis by 69.1% during the third quarter. Adirondack Trust Co. now owns 389 shares of the company’s stock worth $40,000 after purchasing an additional 159 shares in the last quarter. Hedge funds and other institutional investors own 13.12% of the company’s stock.
Novartis Stock Performance
NYSE:NVS opened at $97.44 on Friday. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.90 and a quick ratio of 0.93. Novartis AG has a 1-year low of $92.19 and a 1-year high of $108.78. The business has a 50 day moving average of $97.87 and a 200 day moving average of $98.99. The company has a market capitalization of $199.17 billion, a price-to-earnings ratio of 13.15, a PEG ratio of 1.59 and a beta of 0.54.
Novartis Increases Dividend
The business also recently disclosed an annual dividend, which was paid on Thursday, March 7th. Shareholders of record on Friday, March 8th were given a $3.7772 dividend. The ex-dividend date was Thursday, March 7th. This represents a yield of 3.1%. This is an increase from Novartis’s previous annual dividend of $3.47. Novartis’s payout ratio is presently 32.79%.
Analysts Set New Price Targets
NVS has been the subject of several recent analyst reports. BMO Capital Markets boosted their price objective on Novartis from $114.00 to $116.00 and gave the stock a “market perform” rating in a report on Wednesday. Morgan Stanley initiated coverage on Novartis in a report on Tuesday, January 23rd. They set an “equal weight” rating and a $114.00 price objective for the company.
Read Our Latest Stock Analysis on Novartis
About Novartis
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.
Featured Stories
- Five stocks we like better than Novartis
- Do ETFs Pay Dividends? What You Need to Know
- MarketBeat Week in Review – 4/22 – 4/26
- Investing in the High PE Growth Stocks
- 3 Stocks Leading the U.S. Agriculture Comeback
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- How to Use Put Debit Spreads to Profit From Falling Stocks
Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS – Free Report).
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.